John Longenecker Email & Phone Number

San Diego, CA, US

Executive consulting for the biopharmaceutical industry

Greater San Diego Area

Pacira is a specialty pharmaceutical company which went public in Feb of 2011 (PCRX). It is the latest evolution of DepoTech/SkyePharma in the U.S. with corporate HQ in NJ and manufacturing and R&D operations in San Diego. The U.S. assets of Skye were repurchased by a VC investor group in 2007 and taken private as Pacira Pharmaceuticals, at which time I.

Cambridge MA

Greater San Diego Area

Hemaquest is a private, virtual bio therapeutics company developing a prophylaxis for the prevention of pain crisis and associated clinical events in patients with sickle cell disease. The company initiated a second phase 2 clinical program in Q2 of 2012. An interim analysis of this trail was conducted in November of 2013 which indicated no statistically.

Greater San Diego Area

I joined in February of 2002 and closed a Series B venture round that spring. The company went through 2 additional private rounds and I took the company public (NASDAQ - FVRL) in Feb 2005. We grew from 10 to about 165 employees, built a cGMP mfg facility in 2004 and completed a phase 3 clinical trial of a personalized therapeutic vaccine for indolent non.

San Diego, CA - London UK

DepoTech was acquired by SkyePharma plc in April 1999 and I became President of the U.S. subsidiary and a member of the Management Committee of SkyePharma plc. Our first product (DepoCyte) was approved in April 1999 and launched in the U.S. and Europe.

I joined DepoTech as the first executive manager in November of 1992 when the Company had less than 10 employees and a single venture investor. Within a month we raised a Series A round and over the next 7 years grew from a concept with some lab generated product and a little clinical data to a NASDAQ listed public company (1995) with a completed phase 3.

I joined Cal Bio (later know as Scios) as Scientist and first Ph.D. employed by the company in 1982. I was fortunate to be able to take on greater responsibility in the evolving organization and became V.P. of Development in 1986. I first established, staffed and built out the facilities to support preclinical development, pharmaceutical development.

Post Doc, Biochemistry

My post doc work focused on the effect of glucocorticoids on vascular cell biology, specifically inflammation and arteriosclerosis. We.

Ph.D, Biochemistry

Bs, Chemistry/Education